Condition

Gall Bladder Cancer

ClinicalTrials.gov condition label

Clinical trials8

Recruiting7

Common interventions14

Lead sponsors shown8

Clinical trials

8 shown

Distance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11

DESTINY-PANTUMOUR04NCT07124000 · 2025-09-18

Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersNCT07337850 · 2024-09-25

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerNCT06852287 · 2024-09-01

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesNCT05000294 · 2021-12-07

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers ScreeningNCT07176962 · 2020-01-01

B-Receptor Signaling in CardiomyopathyNCT01135849 · 2008-11-01

Common interventions

AccelerometryPROCEDURE1 Aerobic Exercise InterventionOTHER1 AtezolizumabDRUG1 chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.DRUG1 Electronic Health Record ReviewOTHER1 Exercise interventionOTHER1 gallium-68-Fibroblast Activation Protein InhibitorDIAGNOSTIC_TEST1 InterviewOTHER1 pembrolizumabDRUG1 Questionnaire AdministrationOTHER1 rezatapoptDRUG1 TelemedicineOTHER1 TivozanibDRUG1 Trastuzumab deruxtecanDRUG1

Leading sponsors

Alliance for Clinical Trials in Oncology1 AstraZeneca1 Daniel Bernstein1 PMV Pharmaceuticals, Inc1 Tata Memorial Centre1 Tianjin Medical University Cancer Institute and Hospital1 University of Florida1 Yingbin Liu, MD, PhD, FACS1

Trial status mix

RECRUITING7

COMPLETED1

Phase mix

PHASE23

PHASE12

NA1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.